EE64 Treatment-Related Costs of Ponatinib and Asciminib in Adults Patients with T315I-Positive Chronic Phase Chronic Myeloid Leukemia with Resistance or Intolerance to at Least Two Prior Kinase Inhibitors in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.364
https://www.valueinhealthjournal.com/article/S1098-3015(24)00479-0/fulltext
Title :
EE64 Treatment-Related Costs of Ponatinib and Asciminib in Adults Patients with T315I-Positive Chronic Phase Chronic Myeloid Leukemia with Resistance or Intolerance to at Least Two Prior Kinase Inhibitors in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00479-0&doi=10.1016/j.jval.2024.03.364
First page :
Section Title :
Open access? :
No
Section Order :
11708